NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled
NCT01273597 2013-01-18Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid GlandsAbbVieCompleted60 enrolled 11 charts